BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion ...

The result is a major disappointment for BMS as it effectively cuts the potential market for Camzyos in half. Sales of the ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

A New York City federal court has dismissed a proposed class-action lawsuit against Bristol Myers Squibb that accused the ...

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action ...

US pharma major Bristol Myers Squibb (NYSE: BMY) yesterday disclosed that its Phase III ODYSSEY-HCM trial of Camzyos ...